Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in ENHANCE-1 and ENHANCE-2. We are led by a management team with an established track record in the discovery, development and commercialization of respiratory therapies. Verona Pharma is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA. We are headquartered in London, UK, and have offices in Raleigh and Savannah in the US. For more information, please visit https://www.veronapharma.com.
Unlock the market timeline & signal feed
The order this company entered each market — oldest to newest
New drug application for COPD treatment accepted in China
New drug application for COPD treatment accepted in China
Sign up to see the full signal feed
How Verona Pharma's international expansion compares to its competitors
Verona PharmaYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Verona PharmaYou | 0 | 0 | 0% | 0 | 18 |
Medical Science Liaison
View postingCalifornia, United States · last yr.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Nuance Pharma's Phase 3 ENHANCE-CHINA trial for nebulized ensifentrine in COPD treatment met primary and secondary endpoints, showing significant lung function improvements and reduced exacerbation rates.
Nuance Pharma's ENHANCE-CHINA trial for Ensifentrine in COPD shows significant lung function improvement, quality of life enhancement, and reduced exacerbation risk. NDA submission planned for late 2025.
Nuance Pharma's ENHANCE-CHINA trial for Ensifentrine in COPD treatment shows significant lung function improvement, quality of life enhancement, and reduced exacerbation risk.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Verona Pharma's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
